DeepMed Research

Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Estrogen Receptor Negative
HER2/Neu Negative
Prognostic Stage IV Breast Cancer AJCC v8
Triple-Negative Breast Carcinoma
Progesterone Receptor Negative

Interventions: Biological: Durvalumab
Drug: Olaparib

First Posted Date: 2018-06-01

Last Posted Date: 2020-11-20

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 3

Registration Number: NCT03544125

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Exercising Together During Radiation Treatment

Not Applicable

Completed

Conditions: Prostate Carcinoma
Spouse
Domestic Partnership

Interventions: Behavioral: Exercise Intervention
Other: Questionnaire Administration
Other: Survey Administration

First Posted Date: 2018-02-01

Last Posted Date: 2020-10-08

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 24

Registration Number: NCT03418025

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Internet-Based Exercise and Diet Support in Prostate Cancer Survivors

Not Applicable

Completed

Conditions: Cancer Survivor
Prostate Carcinoma

Interventions: Behavioral: Written Information
Behavioral: Prescription
Behavioral: Technology
Behavioral: Coaching

First Posted Date: 2018-01-23

Last Posted Date: 2020-07-29

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 206

Registration Number: NCT03406013

Locations: 🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Liposarcoma
Malignant Abdominal Neoplasm
Malignant Retroperitoneal Neoplasm
Malignant Scrotal Neoplasm
Malignant Solid Neoplasm
Malignant Spermatic Cord Neoplasm

Interventions: Drug: Eribulin Mesylate
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2017-12-04

Last Posted Date: 2025-04-02

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 15

Registration Number: NCT03361436

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Phase 2

Active, not recruiting

Conditions: Glioblastoma

Interventions: Drug: Ferumoxytol
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab

First Posted Date: 2017-11-20

Last Posted Date: 2024-04-17

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 56

Registration Number: NCT03347617

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

Phase 2

Terminated

Conditions: Lung Carcinoma Metastatic in the Brain
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Ferumoxytol
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab

First Posted Date: 2017-10-30

Last Posted Date: 2022-08-10

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03325166

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer

Early Phase 1

Terminated

Conditions: Locally Advanced Rectal Carcinoma
Stage III Rectal Cancer AJCC v7
Stage IIIA Rectal Cancer AJCC v7
Stage IIIB Rectal Cancer AJCC v7
Stage IIIC Rectal Cancer AJCC v7

Interventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging
Drug: Ferumoxytol

First Posted Date: 2017-09-12

Last Posted Date: 2021-09-10

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03280277

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Phase 2

Recruiting

Conditions: Cranial Nerve Disorder
Central Nervous System Neoplasm
Metastatic Malignant Neoplasm in the Brain

Interventions: Drug: Ferumoxytol
Drug: Gadolinium
Procedure: Magnetic Resonance Imaging

First Posted Date: 2017-09-01

Last Posted Date: 2025-02-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 150

Registration Number: NCT03270059

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer

Not Applicable

Withdrawn

Conditions: Head and Neck Carcinoma

Interventions: Other: Best Practice
Other: Laboratory Biomarker Analysis
Dietary Supplement: Nutritional Intervention

First Posted Date: 2017-08-24

Last Posted Date: 2020-02-25

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT03261180

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors

Phase 2

Withdrawn

Conditions: Brain Neoplasm

Interventions: Drug: Ferumoxytol
Procedure: Magnetic Resonance Imaging

First Posted Date: 2017-07-31

Last Posted Date: 2021-11-10

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT03234309

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy